Hansa Biopharma, “Hansa”, today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of ...

Annexon Biosciences CEO Doug Love considers Guillain-Barré syndrome — also known as GBS — to be the “most unique disease” he’s worked on in 25 years in biotech because of its sudden onset. A rare ...

The FDA granted Pfizer a breakthrough therapy designation for its group B Streptococcus vaccine candidate for pregnant people to prevent GBS disease in newborns based on its ongoing phase 2 trial. GBS ...

Thanks to the relentless efforts of medical researchers around the world, several different messenger ribonucleic acid (mRNA) and vector-based vaccines were authorized for use by regulatory bodies ...

Two persons have died after an outbreak of Guillain-Barré Syndrome, an immunological nerve disorder, in Madhya Pradesh’s Neemuch district, prompting the government to launch a drive to identify ...